Natera
Natera is a pioneer in molecular disease monitoring, offering a market-leading portfolio of ultra-sensitive assays and real-word data to support clinical development.
Natera’s flagship assay, Signatera™, is a tumor-informed circulating tumor DNA (ctDNA) assay developed for molecular residual disease (MRD) detection, recurrence monitoring, and treatment response monitoring. Signatera™ is supported by 100+ publications across 30+ tumor types and is covered by Medicare for eligible patients with CRC, breast cancer, NSCLC, MIBC, ovarian cancer, and patients receiving IO.
Leveraging its robust commercial footprint, Natera is transforming patient care—40% of U.S. oncologists are ordering, 300K+patients have been tested, and 1.2M+ Signatera™ tests have been ordered to date. Natera brings together technological innovation, a deep commitment to evidence building, and a proven ability to operationalize and commercialize at scale.
